Cristiana Guiducci, Ph.D.

Cristiana Guiducci, Ph.D., has served as Senior Vice President, Immunology and Oncology Research of Nurix since January 2021 and served as the company’s Vice President, Immunology and Oncology Research from 2019 through 2020. Prior to joining Nurix, Cristiana Guiducci was the Vice President of Oncology Research at Dynavax Technologies where she directed all foundational research leading to the development of the Dynavax immuno-oncology assets. Prior to her work in oncology, she directed the discovery and characterization of drug candidates for autoimmune diseases at Dynavax. She received her bachelor and master’s degrees in molecular biology from University of Rome, Italy and her Ph.D. in immunology from the Open University of London, UK. She completed her post-doctoral training at National Tumor Institute in Milan, Italy.

Robert J. Brown, M.D.

Robert J. Brown, M.D. has served as Senior Vice President of Clinical Development since January 2021 and served as the company’s Vice President of Clinical Development from June through December 2020. He is trained as a pediatric neuro-oncologist with a decade of immunotherapy drug development expertise. Prior to joining Nurix, Dr. Brown led cellular therapy development programs in both solid tumors and hematologic malignancies, including allogeneic CAR-T cells at Allogene and tumor infiltrating lymphocytes at Iovance Biotherapeutics. Dr. Brown’s training includes pediatric oncology at the Yale School of Medicine and the treatment of pediatric brain and spinal cord tumors at Children’s Hospital Los Angeles and University of Southern California. He completed a postdoctoral fellowship in radiation-induced brain injury at UCLA, focusing on the role of long-term inflammation on brain development, repair, and dementia. He holds a B.Sc. in chemistry from the Massachusetts Institute of Technology and an M.D. from the Weill Cornell Medical College in New York.

Jason Kantor, Ph.D.

Jason Kantor, Ph.D. has served as Senior Vice President, Finance and Investment Strategy of Nurix since July 2020. Prior to joining Nurix, Dr. Kantor served as a senior biopharma analyst at Artisan Partners, where he covered industry trends for both large and small cap biotech and pharma companies globally. He also served as board president at Biotech Partners, meeting the non-profit’s goals of increasing corporate sponsorship and gaining support from local government. Dr. Kantor previously served as managing director, biotechnology analyst at Credit Suisse, RBC Capital Markets and WR Hambrecht + Co, focusing on innovative biotech companies and building successful healthcare and research franchises. Prior to that, he held a position as vice president, biotechnology analyst at JP Morgan Chase & Co. Dr. Kantor holds a B.A. in biology from the University of California, San Diego and a Ph.D. in cell and development biology from Harvard University.

Christine Ring, Ph.D., J.D.

Christine Ring, Ph.D., J.D., has served as Secretary of Nurix since March 2020 and as the company’s General Counsel since September 2019. Prior to joining Nurix, Dr. Ring held multiple positions assisting companies protect intellectual property, engage in licensing transactions, raise capital, and transition from private companies into public companies. Her most recent corporate positions were as Senior Vice President, Legal at Dermira, Inc., a biotechnology company focused on medical dermatology, and as Senior Vice President of Technology, Strategy & Licensing at Amyris, Inc., a biotechnology company focused on renewable fuels and specialty chemicals. Dr. Ring holds an A.B. in Biophysics from the University of California, Berkeley, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and a J.D. from the University of California, Hastings College of the Law.

Michael T. Lotze, M.D.

Michael T. Lotze, M.D. has served as Chief Cellular Therapy Officer of Nurix since June 2020. He is a leading clinician scientist with more than 30 years of experience in immunology and clinical medicine, dedicating his efforts to the advancement of translational research, particularly in immunotherapy for cancer including dendritic cell, T cell, and cytokine therapies. Dr. Lotze is the co-inventor of multiple patents in dendritic cell vaccines and antigen discovery, and tumor infiltrating lymphocyte therapy. He previously held leadership roles in the biopharmaceutical industry as the chief scientific officer of Iovance Biotherapeutics and vice president of research at GlaxoSmithKline. Prior to joining Nurix, Dr. Lotze served as professor of surgery, immunology, and bioengineering, vice chair of research within the Department of Surgery and director for Damage Associated Molecular Pattern Molecule (DAMP) Laboratories at the University of Pittsburgh Medical Center Hillman Cancer Center. He was also senior advisor for the Immune Transplant and Therapy Center within the University of Pittsburgh Medical Center Enterprises and serves as associate editor of the Journal of Immunotherapy. Over the course of his career, he has authored more than 500 publications and several books. Dr. Lotze holds an M.D. from Northwestern University and completed his postdoctoral training as a scientist at the National Cancer Institute under Dr. Steven Rosenberg.

Stefani A. Wolff

Stefani A. Wolff has served as Chief Operating Officer and Executive Vice President of Product Development since June 2021. Ms. Wolff is a Board Member at Rain Therapeutics Inc., a precision oncology company, and previously served in a variety of roles at Principia Biopharma Inc., including as Chief Development Officer from August 2018 to September 2020, and as Senior Vice President of Strategy and Operations from January 2017 to August 2018. From May 2013 until December 2015, she was Vice President of Development at Onyx Pharmaceuticals, Inc. and participated in the company’s transition to Amgen. Ms. Wolff spent significant time at Genentech, Inc. and participated in founding the Oncology business, including commercially launching Rituxan in 1997 and building the BioOncology brand, and in development leading the B-cell therapy portfolio across multiple molecules. Early in her career she served in a variety of roles at Eli Lilly & Co. Ms. Wolff earned her B.A. in Chemistry and B.S. in Pharmacy from the University of North Carolina, Chapel Hill.

Gwenn M. Hansen, Ph.D.

Gwenn M. Hansen, Ph.D. has served as Chief Scientific Officer of Nurix since June 2020 and served as the company’s Senior Vice President, Research from July 2019 through May 2020. Since joining Nurix in 2015, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery in addition to leading the discovery organization. Prior to joining Nurix, Gwenn was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and served in a variety of discovery-focused roles at Lexicon Pharmaceuticals. Dr. Hansen holds a B.A. in Biology from Gustavus Adolphus College and a Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville.

Hans van Houte

Hans van Houte has served as Chief Financial Officer of Nurix since June 2020 and has led the company’s finance team since 2015. Prior to joining Nurix, Mr. van Houte was a managing partner at Bionation LLC, a financial consulting firm, and served as acting CFO for multiple new biotechnology companies formed with investments totaling over $150 million from Third Rock Ventures and The Column Group. Mr. van Houte previously held senior financial roles in biotechnology companies including Vice President, Finance and Operations at Trubion Pharmaceuticals, Inc., where he was part of the team that took Trubion public in October 2006. Prior to Trubion, Mr. van Houte was the Controller, Treasurer, and Principal Accounting Officer at Vertex Pharmaceuticals, where he helped build the financial and accounting organization post-IPO to support growth from a $100 million to a multibillion market capitalization. Mr. van Houte holds a B.S. in Business Administration, Finance and Accounting from Babson College..

Arthur T. Sands, M.D., Ph.D.

Arthur T. Sands, M.D., Ph.D., has served as President of Nurix since June 2020, and as Chief Executive Officer and a member of the company’s board of directors since September 2014. Prior to joining Nurix, Dr. Sands was the co-founder and served as President, Chief Executive Officer, and as a member of the board of directors of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on target validation and pharmaceutical development, from 1995 to July 2014. Before founding Lexicon Pharmaceuticals, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. Dr. Sands holds a B.A. in Economics and Political Science from Yale University and an M.D. and a Ph.D. in Cell Biology from Baylor College of Medicine.